Overview

Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Status:
Completed

Trial end date:
2012-02-01

Target enrollment:

Participant gender:

Summary

The investigators anticipate that the use of Glargine will decrease the duration of an insulin drip, the dose of short-acting insulin in the drip, hospital and ICU (intensive care unit) length of stay, improve glycemic control, and prevent rebound hyperglycemias when the insulin drip is discontinued.

Phase:

Phase 1

Details

Lead Sponsor:

University of Colorado, Denver

Collaborator:

Sanofi

Treatments:

Insulin
Insulin Glargine
Insulin, Globin Zinc